10058-F4: Advanced Small-Molecule c-Myc-Max Dimerization Inhibitor Workflows

Understanding the Principle: 10058-F4 and c-Myc/Max Heterodimer Disruption

10058-F4 is a novel, cell-permeable small-molecule c-Myc inhibitor designed to target the critical heterodimerization between c-Myc and Max. This interaction is indispensable for c-Myc transcription factor activity, which drives cell proliferation, survival, and metabolic reprogramming in a range of malignancies, including acute myeloid leukemia (AML) and prostate cancer. By selectively preventing c-Myc/Max dimer formation, 10058-F4 suppresses c-Myc-driven gene expression, leading to cell cycle arrest and apoptosis, primarily via the mitochondrial apoptosis pathway.

Recent mechanistic studies have revealed that c-Myc/Max complexes also regulate telomerase (TERT) expression in human pluripotent stem cells. Notably, a 2024 preprint demonstrated that inhibition of c-Myc:Max dimerization with small molecules like 10058-F4 rapidly increased repressive H3K27me3 marks at the TERT promoter, sharply repressing TERT transcription. This positions 10058-F4 as a powerful tool not only in oncology but also in the study of stem cell self-renewal and telomere biology.

With a molecular weight of 249.35 and high solubility in DMSO (≥24.9 mg/mL) and ethanol (≥2.64 mg/mL), but insolubility in water, 10058-F4 is provided as a solid and should be stored at -20°C. For experimental reliability, freshly prepared solutions are recommended, as long-term storage of solutions can degrade activity.

Optimizing Your Experimental Workflow with 10058-F4

1. Reagent Preparation and Handling

• Stock Solution: Dissolve 10058-F4 in DMSO to create a 10–100 mM stock solution. Vortex gently and sonicate if necessary. Filter sterilize using a 0.22 μm filter.
• Aliquoting: Divide into single-use aliquots to avoid repeated freeze-thaw cycles; store at -20°C.
• Working Concentration: For most apoptosis and c-Myc transcription factor inhibition assays, optimal results are observed at 50–100 μM. For AML cell lines (HL-60, U937, NB-4), 100 μM for 72 hours induces robust, dose-dependent apoptosis.
• Vehicle Controls: Always include matched DMSO controls (<1% final concentration) to account for solvent effects.

2. Cell-Based Assay Protocols

• Apoptosis Assays: Seed cells at log-phase density. Add 10058-F4 at desired concentration. For AML models, monitor apoptosis using Annexin V/PI staining and flow cytometry at 24, 48, and 72 hours. Expect a significant increase in apoptotic cells at 100 μM after 72 hours, as validated in peer-reviewed and vendor data.
• Cell Cycle Analysis: Following treatment, fix cells in ethanol and stain with PI for DNA content analysis. 10058-F4 typically induces G0/G1 arrest in c-Myc-dependent lines.
• Mitochondrial Pathway Activation: Assess cytochrome C release and Bcl-2 family protein modulation by Western blot. Increased cytochrome C in cytosolic fractions and decreased Bcl-2/Bcl-xL signify mitochondrial apoptosis pathway engagement.
• Gene Expression Studies: Use qRT-PCR to quantify c-Myc and downstream targets (e.g., TERT, as in the referenced study) post-treatment.

3. In Vivo Application: Prostate Cancer Xenograft Models

• For mouse models (e.g., SCID mice bearing DU145 or PC-3 xenografts), administer 10058-F4 intravenously at protocol-driven dosages (refer to 10058-F4 product page for detailed guidance).
• Monitor tumor volume bi-weekly. Published data indicate notable tumor growth inhibition, though inter-model variability may occur.
• Always include vehicle and positive controls for rigorous interpretation.

Advanced Applications and Comparative Advantages

1. Beyond Apoptosis: Telomerase and Stem Cell Regulation

The application of 10058-F4 extends to stem cell biology, as highlighted in the MEK1/2-c-Myc:MAX-TERT study. Here, low-dose 10058-F4 not only diminished c-Myc-dependent gene expression but also triggered rapid chromatin remodeling at the TERT promoter, resulting in telomerase repression. This reveals a gateway for dissecting telomere maintenance and stem cell aging.

2. Comparative Mechanistic Insights

• 10058-F4: Small-Molecule c-Myc-Max Inhibitor for Apoptosis complements these findings by detailing how 10058-F4 unlocks new experimental avenues for apoptosis and cancer biology, focusing on protocol optimizations for cell-based assays. Together, these resources foster an integrated understanding of c-Myc/Max axis disruption.
• 10058-F4 (SKU A1169): Reliable c-Myc-Max Dimerization Inhibitor extends practical insights, offering a scenario-driven guide to achieving reproducible results in AML and prostate cancer models. It also provides workflow pointers tailored for lab technicians and biomedical researchers.

3. Why Choose 10058-F4 from APExBIO?

APExBIO is recognized for its high-purity, batch-tested reagents. 10058-F4’s robust batch-to-batch consistency and detailed technical documentation ensure experimental reproducibility across apoptosis assays and c-Myc/Max heterodimer disruption research. Its cell-permeability, selective mechanism, and well-characterized solubility profile distinguish it from less specific c-Myc or Max inhibitors.

Troubleshooting and Optimization Tips

• Solubility Issues: If 10058-F4 does not fully dissolve, gently warm the DMSO solution (up to 37°C) and vortex. Avoid excessive heating or prolonged sonication to prevent degradation.
• Compound Stability: Prepare fresh working solutions immediately before use. Discard any unused solution after each experiment, as extended storage (>24 hours) can reduce activity.
• Cell Line Sensitivity: Sensitivity to c-Myc-Max dimerization inhibition varies. Begin with 10–25 μM in sensitive lines and titrate upwards, monitoring cytotoxicity. For AML and prostate cancer lines, 100 μM is well-tolerated for up to 72 hours, with pronounced apoptosis induction.
• Off-Target Effects: Incorporate genetic controls (e.g., c-Myc knockdown) where possible to validate on-target outcomes and distinguish from non-specific cytotoxicity.
• Assay Interference: DMSO concentrations >1% can confound results, especially in mitochondrial assays. Optimize vehicle concentration accordingly.
• Readout Timing: Time course optimization is critical. Early (6–24 h) readouts are ideal for transcriptional changes (e.g., TERT repression), while late (48–72 h) readouts capture apoptosis phenotypes.

Future Outlook: Expanding the Reach of c-Myc/Max Inhibition

The utility of 10058-F4 is poised to expand alongside advances in cancer biology, regenerative medicine, and chromatin regulation. Integration with multi-omics profiling, single-cell analyses, and organoid models will enable deeper mechanistic insights into c-Myc/Max-dependent transcriptional networks. As highlighted in the Disrupting c-Myc/Max: Mechanistic Insights article, emerging evidence links c-Myc/Max inhibition to DNA repair modulation and novel telomerase regulatory pathways, opening new frontiers for both apoptosis assay development and stem cell aging studies.

Furthermore, the demonstrated efficacy in AML and prostate cancer xenograft models sets the stage for translational research, including combination therapies targeting c-Myc/Max and other oncogenic circuits. Continued mechanistic interrogation, as well as the development of next-generation small-molecule c-Myc inhibitors, will further solidify the central role of 10058-F4 in apoptosis, telomere biology, and cancer research.

For detailed protocols, batch information, and technical support, visit the 10058-F4 product page from APExBIO, your trusted supplier for high-quality research reagents.